High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436 BMS-186295) in human plasma and urine

被引:42
作者
Chang, SY
Whigan, DB
Vachharajani, NN
Patel, R
机构
[1] Bristol Myers Squibb, Pharmaceut Res Inst, Dept Metab & Pharmacokinet, New Brunswick, NJ 08903 USA
[2] Princeton Univ, Princeton, NJ 08543 USA
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 702卷 / 1-2期
关键词
irbesartan; SR; 47436; BMS-186295; angiotensin II antagonist;
D O I
10.1016/S0378-4347(97)00387-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A selective, accurate, precise and reproducible high-performance liquid chromatographic assay was developed for the quantitation of irbesartan, an angiotensin II antagonist, in human plasma and urine samples, The method involved solid-phase extraction of irbesartan and internal standard (I.S.) using a 100-mg Isolute CN cartridge. A portion of the eluate was injected onto an ODS analytical column connected to a fluorescence detector that was set at an excitation wavelength of 250 nm and an emission wavelength of 371 nm. The mobile phase consisted of 50% acetonitrile and a 50% weak phosphate-triethylamine solution, pH 3.5, at a flow-rate of 0.8 ml/min. The assay was linear from 1 to 1000 ng/ml with both plasma and urine. In either matrix, the lower limit of quantitation was 1 ng/ml. The analyses of quality control samples indicated that the nominal values could be predicted with an accuracy >95%. The inter- and intra-day coefficients of variation for the analyses in both matrices were <8%. Irbesartan was stable in both human plasma and urine for at least seven months at -20 degrees C. The application of the assay to a pharmacokinetic study is described. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 12 条
[1]  
CAZAUBON C, 1993, J PHARMACOL EXP THER, V265, P826
[2]  
Chandra T. D., 1996, Proceedings of the Fifteenth Annual ACM Symposium on Principles of Distributed Computing, P322, DOI 10.1145/248052.248120
[3]   ANGIOTENSIN-II RECEPTOR BLOCKADE - AN INNOVATIVE APPROACH TO CARDIOVASCULAR PHARMACOTHERAPY [J].
EBERHARDT, RT ;
KEVAK, RM ;
KANG, PM ;
FRISHMAN, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (11) :1023-1038
[4]  
Gibaldi M., 1982, PHARMACOKINETICS, P409
[5]   HEMODYNAMIC AND NEUROHORMONAL EFFECTS OF THE ANGIOTENSIN-II ANTAGONIST LOSARTAN IN PATIENTS WITH CONGESTIVE-HEART-FAILURE [J].
GOTTLIEB, SS ;
DICKSTEIN, K ;
FLECK, E ;
KOSTIS, J ;
LEVINE, TB ;
LEJEMTEL, T ;
DEKOCK, M .
CIRCULATION, 1993, 88 (04) :1602-1609
[6]  
LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387
[7]   DESIGN OF SPECIFIC INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME - NEW CLASS OF ORALLY ACTIVE ANTIHYPERTENSIVE AGENTS [J].
ONDETTI, MA ;
CUSHMAN, DW .
SCIENCE, 1977, 196 (4288) :441-444
[8]  
RIBSTEIN J, 1994, J HYPERTENS S3, V12, P131
[9]   THE APPLICATION OF STATISTICAL MOMENT THEORY TO THE EVALUATION OF INVIVO DISSOLUTION TIME AND ABSORPTION TIME [J].
RIEGELMAN, S ;
COLLIER, P .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1980, 8 (05) :509-534
[10]  
SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249